 |
Investor Relations
|
Vitro CEO Interviews with Wall Street Reporter Regarding New Stem Cell Tools for Cellular Medicine
May 20, 2010
Golden, Colorado—May 20, 2010—Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced that its CEO, Dr. James Musick was interviewed regarding the Company’s current results and future prospects. The audio interview may be accessed through the following link:
VitroDiagnostics
Safe Harbor Statement
Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Dr. James Musick
Chief Executive Officer
Vitro Diagnostics, Inc.
(303) 999-2130
E-mail: jim@vitrodiag.com
Source: Vitro Diagnostics, Inc.